Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...
B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results